Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q2 2024 Earnings Conference Call July 29, 2024 8:30 AM ET
Company Participants
Chris Ward - Senior Director, Investor Relations
Stuart Essig - Executive Chairman
Jan De Witte - President and Chief Executive Officer
Lea Knight - Chief Financial Officer
Conference Call Participants
Kristen Stewart - C.L. King
Steve Lichtman - Oppenheimer and Company
Matt Taylor - Jefferies
Ryan Zimmerman - BTIG
Robbie Marcus - JPMorgan
Jayson Bedford - Raymond James
Craig Bijou - Bank of America Securities
Richard Newitter - Truist Securities
Joanne Wuensch - Citi
Vik Chopra - Wells Fargo
Operator
Good day, and welcome to the Integra LifeSciences Second Quarter 2024 Financial Results. At this time all participants’ are in a listen-only mode. After the speakers’ presentation there will be a question-and-answer session. [Operator Instructions] As a reminder this call is being recorded.
I would now like to turn the call over to Chris Ward, Senior Director, Investor Relations. Please go ahead.
Chris Ward
Thank you. Good morning, and thank you for joining the Integra Integra LifeSciences second quarter 2024 earnings conference call.
With me on the call are Stuart Essig, Executive Chairman; Jan De Witte, President and Chief Executive Officer; and Lea Knight, Chief Financial Officer.
Earlier this morning, we issued a press release announcing our second quarter 2024 financial results. The release and corresponding earnings presentation, which we will reference during the call are available at integralife.com under Investors, Events and Presentations and a file named second quarter 2024 earnings call presentation.
Before we begin, I want to remind you that many of the statements made during this call may be considered forward-looking. Factors that could cause actual results to differ materially are discussed in the company's Exchange Act reports filed with the SEC and in the release. Also in our prepared remarks, we will reference reported and organic revenue growth and organic revenue growth excluding Boston. Organic revenue growth excludes the effects of foreign currency, acquisitions and divestitures. Organic revenue growth, excluding Boston, excludes revenues from products manufactured in our Boston facility in both periods.
Management believes that excluding revenue from all products manufactured at Boston at the Boston plant provides useful information when evaluating the company's organic growth, because of the unusual nature of the manufacturing stoppage and voluntary global recall. Unless otherwise stated, all disaggregated and franchise level revenue growth rates are based on organic performance.
Lastly, our comments today will include certain non-GAAP financial measures. Reconciliations of non-GAAP financial measures can be found in today's press release, which is an exhibit to Integra's current report Form 8-K filed with the SEC.